Glutathione Uses and Side Effects What is Glutathione? Glutathione is a substance made from the amino acids glycine, cysteine and glutamic acid. It is produced by your liver and involved in many body processes. Glutathione is involved in tissue building and repair, making chemicals and proteins needed in the body, and in immune system function. What are the Different Name of Glutathione? Gamma-Glutamylcysteinylglycine Gamma-L-Glutamyl-L-Cysteinylglycine Gamma-L-Glutamyl-L-Cystéinylglycine Glutathion, Glutatión L-Gamma-Glutamyl-L-Cysteinyl-Glycine L-Gamma-Glutamyl-L-Cystéinyl-Glycine L-Glutathion L-Glutathione GSH N-(N-L-gamma-Glutamyl-L-cysteinyl)glycine Why should I take Glutathione? There are few good uses of Glutathione. People take glutathione for aging, alcohol use disorder, liver disease, heart disease, and many other conditions, but there is no good scientific evidence to support these
The Scary Part of the New Coronavirus
Recently, a very serious new coronavirus infection broke out in my country. But many people, especially middle-aged and elderly people, disagree that the severity of this infection has not reached a high level. This is an extremely wrong understanding. The infectious power of the new coronavirus is far higher than that of the SARS virus. The total number of people infected with the SARS virus on a global scale that year was only more than 8,000, and the total epidemic lasted for more than one year. The new coronavirus in Wuhan has already infected more than 800 people in just one week. If the virus can last for a year, the consequences will be so serious that I can hardly imagine. That is to say, in terms of infectivity, the new coronavirus is a hundred times the SARS virus.
In terms of fatality rate, the SARS virus is five times that of the new coronavirus in the death statistics, but we must consider an objective environment. The level of medical care in China 17 years ago is far lower than it is now, which means that if SARS occurs now, the mortality rate will never reach the high level of the year.
On the contrary, if the current new type of coronavirus occurred in that year, the mortality rate would inevitably skyrocket. So the objectively true fatality rate, even if the SARS virus is stronger than the new coronavirus, is definitely not five times the so-called so-called. Then let's objectively analyze which virus is more harmful than SARS virus or new coronavirus. The answer is yes. The new coronavirus must be more serious. Because the ultimate severity is actually the product of infectiousness and lethality.
Also Refer: Vaccine Development Encyclopedia
Obviously, the advantage of the novel coronavirus in infectiousness is not comparable to that of the SARS virus in terms of mortality. So in the face of a virus that is more terrible than SARS, how can we not pay attention to it?
If everyone wants to have a longer lifespan, then we can hope everyone can wear a mask when going out, eat less game and go to the wild.
In the hardest-hit areas, especially Wuhan,
it is best to reduce the time for gatherings, so as not to go out without going
out, to reduce the time to travel abroad. Only when everyone does this can the
infectivity of the new coronavirus be truly reduced, and ultimately the result
of complete annihilation of the new coronavirus can be achieved.
Cell: You can prevent the new coronavirus without a vaccine!
Recombinant human ACE2 protein can weaken the infection ability of the new
coronavirus by over a thousand times
The most important, cutting-edge, and most interesting progress in life science research
The new type of coronavirus pneumonia (COVID-19) has evolved
into a global pandemic. The daily real-time update of the epidemic data makes
us daunting. So far, the cumulative number of confirmed cases worldwide has
exceeded 1 million, and the death toll has exceeded 50,000. Academician Zhong
Nanshan said that the global epidemic may not reach an inflection point until
the end of April.
In this regard, many domestic and foreign scholars speculate
that the new coronavirus may be similar to influenza viruses and coexist with
humans for a long time. However, existing data show that the fatality rate of
SARS-CoV-2 is much higher than that of influenza. Therefore, in order to deal
with this worst situation, it is very important to develop vaccines and
preventive drugs against SARS-CoV-2.
Recently, a research team composed of multiple research
institutions in Europe and North America published a study titled: Inhibition
of SARS-CoV-2 infections in engineered human tissues using clinical-grade
soluble human ACE2 in the top international academic journal Cell.
This study puts forward a new idea to prevent SARS-CoV-2 infection: using recombinant human ACE2 protein purified in vitro to "neutralize" new coronaviruses so that they cannot enter human cells, thereby achieving the purpose of preventing infection.
What is Human angiotensin-converting enzyme 2 (hACE2)
Human angiotensin-converting enzyme 2 (hACE2) is a protein on the surface of cell membranes. Many studies have shown that hACE2 is a key receptor for SARS-CoV-2 to invade human cells.
In addition, scientists have
found in mouse models that, in a certain range Inside, the expression level of
hACE2 is positively correlated with the degree of SARS-CoV-2 infection.
These research facts show that hACE2 has a strong affinity
with SARS-CoV-2. So, can we use hACE2 flexibly as a special "antibody"
to "neutralize" SARS-CoV-2 and prevent them Invade human cells?
In this study, the researchers purified clinical-grade recombinant human ACE2 protein (hrsACE2) in vitro. They found that if SARS-CoV-2 is incubated with hrsACE2 for a period of time before SARS-CoV-2 infects cells, the virus's infectivity will be reduced.
A sharp drop, the
weakening range can reach 1000-5000 times. In contrast, if the same experiment
is repeated with the murine ACE2 protein, SARS-CoV-2 infection cannot be
suppressed.
The above research results are limited to the cellular level
and are not convincing enough. Therefore, the researchers applied the
"organoid" model to enhance the reliability of the research.
Studies have shown that COVID-19 may cause severe viremia. In addition, hACE2 is highly expressed in human renal tubules, and the potential risk of SARS-CoV-2 attacking the kidney is great.
In this regard, the
researchers constructed a human capillary model through induced pluripotent
stem cell (iPSCs) technology, and constructed a kidney organ model using human
embryonic stem cells combined with 3D suspension culture technology.
In experiments at the organoid level, the researchers found that, similar to cell experiments, the addition of hrsACE2 can significantly reduce SARS-CoV2 infection, while changing to murine ACE2 protein has no effect.
More
importantly, in the kidney organ model, this inhibitory ability also showed a
significant dose-dependent effect-the higher the concentration of ACE2 protein
added, the stronger the inhibitory ability.
The researchers also further verified the safety of
recombinant ACE2 protein. Preliminary data showed that neither hrsACE2 nor
murine ACE2 protein is toxic to the cells and organoids in the experiment.
In this regard, the main research leader Josef Penninger
said: "Now we know that a soluble ACE2 can effectively inhibit the virus.
This is indeed a very reasonable treatment-specifically for the passage that
the virus must pass when it infects the human body. This There is still hope
for a terrible epidemic."
However, it is worth noting that this study is only for the early stage of SARS-CoV2 infection-invasion of human cells, and whether hrsACE2 can work in the later stage of infection is still unknown.
In addition, the
research is still limited to the level of cells and organs, and is still far
from clinical application. Follow-up studies are still needed to verify the
effectiveness of this therapy at the individual level.
Paper link: https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00739.pdf
Special note: This article only truthfully reports the latest research results
and does not constitute medication guidance.
Name: Gwynneth May
Educational Qualification: MBBS, MD (Medicine) Gold Medalist
Profession: Doctor
Experience: 16 Years of Work Experience as a Medical Practitioner
Comments
Post a Comment